Commission must reconsider GSK's dual pricing system, says ECJ
This article was originally published in Scrip
The European Commission must look again at whether GlaxoSmithKline's dual pricing system in Spain can be exempted from EC competition rules, the European Court of Justice (ECJ) has said.
You may also be interested in...
The Netherlands will secure lower medicine prices by referencing Norway instead of Germany to set maximum prices.
Luxembourg’s new regulator will work to attract investment and improve public health as well as tackle the growing problem of drug shortages.
Better dialogue with companies, together with new regulations and ways of working, have helped Brazil’s medicines regulator set new records for registering pharmaceuticals.